A real-world trial on trastuzumab for cardiotoxicity brought on by HER2-positive breast cancer included more than 3,700 research participants and found a 2.8% incidence of CHF with a 1.0% incidence of severe CHF [21, 22]. The gene discussed is ERBB2; the disease is congestive heart failure.